论文部分内容阅读
应用ｐ２１和表皮生长因子受体（ＥＧＦｒ）单克隆抗体，通过免疫组织化学方法检测正常膀胱组织和膀胱癌组织中ｒａｓ癌基因产物ｐ２１和ＥＧＦｒ的表达状况。结果显示：５例正常膀胱组织中未发现ＥＧＦｒ和ｐ２１阳性表达，阳性表达的ＥＧＦｒ和ｐ２１均定位于肿瘤的细胞膜上。５８例膀胱癌中ＥＧＦｒ和ｐ２１阳性表达率分别为５８．６％（３４／５８）和６２．１％（３６／５８）．并且ＥＧＦｒ和ｐ２１阳性表达率与膀胱癌的病理分级、临床分期和患者术后生存期有关。提示ＥＧＦｒ和ｐ２１阳性表达在膀胱癌发生和发展中起着重要作用，可判别膀胱癌恶性程度和预测膀胱癌的预后。
Using p21 and epidermal growth factor receptor (EGFr) monoclonal antibodies, immunohistochemistry was used to detect the expression of ras oncogene products p21 and EGFr in normal bladder tissues and bladder cancer tissues. The results showed that EGFR and p21 were not found in 5 cases of normal bladder tissue, while EGFR and p21 were localized on the cell membrane of tumor. The positive rates of EGFR and p21 in 58 cases of bladder cancer were 58.6% (34/58) and 62.1% (36/58) respectively. And the positive rate of EGFR and p21 was related to the pathological grade, clinical stage and survival time of bladder cancer. It is suggested that the positive expression of EGFr and p21 plays an important role in the occurrence and development of bladder cancer. It can distinguish the malignant degree of bladder cancer and predict the prognosis of bladder cancer.